An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects with Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study
The primary objective of this open-label extension trial is to evaluate the long-term safety of AXS-05 for the treatment of Alzheimer's disease agitation in subjects that participated in ADVANCE-2 and ACCORD-2.
Efficacy of Bupropion-Dextromethorphan fixed dose combination versus Sertraline in major depressive disorder patients: a non-inferiority randomised controlled trial - NIL
开始日期2024-10-15
申办/合作机构-
100 项与 DAT x adrenergic receptor x σ1 receptor x CYP2D6 x NMDA receptor 相关的临床结果
登录后查看更多信息
100 项与 DAT x adrenergic receptor x σ1 receptor x CYP2D6 x NMDA receptor 相关的转化医学
登录后查看更多信息
0 项与 DAT x adrenergic receptor x σ1 receptor x CYP2D6 x NMDA receptor 相关的专利(医药)